Literature DB >> 14654940

Experimental treatment of human neuroblastoma using live-attenuated poliovirus.

Hidemi Toyoda1, Masaru Ido, Tatsuya Hayashi, Esteban C Gabazza, Koji Suzuki, Rodrick R Kisenge, Jian Kang, Hiroki Hori, Yoshihiro Komada.   

Abstract

Neuroblastoma, originated from neural crest cells, is the most common extracranial solid tumor in childhood. In the present study, we evaluated in vitro the oncolytic effect of live-attenuated poliovirus on human neuroblastoma cell lines, and in vivo its therapeutic efficacy in human neuroblastoma-bearing athymic mice. Live-attenuated poliovirus killed 27 (93%) of 29 established neuroblastoma cell lines in vitro. It induced cleavage of eukaryotic translation initiation factor 4G, leading to cell death through a mechanism involving activation of caspase-9, caspase-3 and poly(ADP-ribose)polymerase. For the in vivo experiments, an animal model was established using athymic mice xenotransplanted with SJ-N-JF neuroblastoma cells on both flanks. Inoculation of live-attenuated poliovirus into one of the two tumors caused a dramatic and complete regression of both the inoculated and contralateral tumors. Live-attenuated poliovirus has potent oncolytic activity against human neuroblastomas in vitro and in vivo and it may be useful for the treatment of advanced and refractory neuroblastomas, however, further studies are necessary to evaluate the safety of method.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14654940

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  9 in total

1.  HsMAD2 mRNA expression may be a predictor of sensitivity to paclitaxel and survival in neuroblastoma.

Authors:  Kohei Otake; Keiichi Uchida; Kouji Tanaka; Yuhki Koike; Mikihiro Inoue; Kohei Matsushita; Motoko Ueeda; Kiyoshi Hashimoto; Takahito Kitajima; Yoshihiro Komada; Masato Kusunoki
Journal:  Pediatr Surg Int       Date:  2011-02       Impact factor: 1.827

2.  Live-attenuated poliovirus-induced extrinsic apoptosis through Caspase 8 within breast cancer cell lines expressing CD155.

Authors:  Hossein Vazeh; Emad Behboudi; Anahita Hashemzadeh-Omran; Abdolvahab Moradi
Journal:  Breast Cancer       Date:  2022-06-01       Impact factor: 3.307

3.  PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells.

Authors:  Lei Qi; Hidemi Toyoda; Dong-Qing Xu; Ye Zhou; Naoto Sakurai; Keishirou Amano; Kentaro Kihira; Hiroki Hori; Eiichi Azuma; Yoshihiro Komada
Journal:  Cancer Cell Int       Date:  2015-09-29       Impact factor: 5.722

4.  Prognostic significance of CD155 mRNA expression in soft tissue sarcomas.

Authors:  Satoru Atsumi; Akihiko Matsumine; Hidemi Toyoda; Rui Niimi; Takahiro Iino; Akihiro Sudo
Journal:  Oncol Lett       Date:  2013-04-02       Impact factor: 2.967

5.  Oral poliovirus vaccine-induced programmed cell death involves both intrinsic and extrinsic pathways in human colorectal cancer cells.

Authors:  Sareh Zhand; Seyed Masoud Hosseini; Alijan Tabarraei; Mohsen Saeidi; Marie Saghaeian Jazi; Mohamad Reza Kalani; Abdolvahab Moradi
Journal:  Oncolytic Virother       Date:  2018-10-30

Review 6.  Oncolytic viruses in cancer therapy.

Authors:  Markus J V Vähä-Koskela; Jari E Heikkilä; Ari E Hinkkanen
Journal:  Cancer Lett       Date:  2007-03-23       Impact factor: 8.679

7.  Nafamostat mesylate prevents metastasis and dissemination of neuroblastoma through vascular endothelial growth factor inhibition.

Authors:  Mari Morimoto; Hidemi Toyoda; Kaori Niwa; Ryo Hanaki; Taro Okuda; Daisuke Nakato; Keishiro Amano; Shotaro Iwamoto; Masahiro Hirayama
Journal:  Mol Clin Oncol       Date:  2022-07-21

8.  Oncolytic Viruses in the Therapy of Lymphoproliferative Diseases.

Authors:  P O Vorobyev; F E Babaeva; A V Panova; J Shakiba; S K Kravchenko; A V Soboleva; A V Lipatova
Journal:  Mol Biol       Date:  2022-10-05       Impact factor: 1.540

9.  Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers.

Authors:  P Seshidhar Reddy; Kevin D Burroughs; Laura M Hales; Shanthi Ganesh; Brian H Jones; Neeraja Idamakanti; Carl Hay; Shawn S Li; Kristine L Skele; Ann-Jeanette Vasko; Jingping Yang; D Neil Watkins; Charles M Rudin; Paul L Hallenbeck
Journal:  J Natl Cancer Inst       Date:  2007-10-30       Impact factor: 13.506

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.